Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications

SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies were presented in four oral Abstract Flash Talk presentations during The Liver Biology Conference: Fundamental Mechanisms...

Click to view original post